This review summarizes the efficacy of nondepolarizing neuromuscular blocking agents in anesthesia, highlighting implications for clinical practice.
Key Points
The review aims to evaluate the effectiveness and safety of nondepolarizing neuromuscular blocking agents, particularly focusing on novel agents like gantacurium and CW002.
Narrative review of existing literature on neuromuscular blocking agents.
Discussion of studies involving isoquinolinium derivatives and pinnatoxins.
Assessment of reversal agents such as L-cysteine and Calabadion.
Gantacurium has completed Phase III clinical trials, showing potential for approval.
CW002 demonstrates fewer cardiovascular and pulmonary side effects, but a longer neuromuscular block.
Calabadion shows faster binding to neuromuscular blockers compared to existing agents like sugammadex.